Oncology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

Catch-up HPV vaccine most effective when initiated early

Roshini Claire Anthony, 12 hours ago

Women who receive their first catch-up dose of the human papillomavirus (HPV) vaccination at a younger age may obtain the most benefits in terms of cancer protection, according to a recent study.

Vitamin D receptor genes tied to bladder cancer recurrence after immunotherapy

Yesterday

Various vitamin D receptor (VDR) single nucleotide polymorphisms appear to predict nonmuscle invasive bladder cancer recurrences after bacillus Calmette-Guérin immunotherapy, suggests a recent study.

5α-reductase inhibitors improve bladder cancer survival

2 days ago

Treatment with 5α-reductase inhibitors improves disease-specific survival following a diagnosis of bladder cancer, suggests a recent study. On the other hand, α-blockers do not appear to improve bladder cancer survival.

A report of the first patient in Malaysia who had successfully completed 16 cycles of brentuximab vedotin

19 Sep 2018

In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.^1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.⁴ Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.⁵

Rapid onset opioids for the optimized treatment of breakthrough cancer pain

24 Jul 2018

At a recent dinner symposium held during the Abstral® Grand Launch at Le Meridien Putrajaya, Dr Michael Überall spoke on the management of breakthrough cancer pain (BTcP) and highlighted the role of sublingual fentanyl ([SLF], Abstral®; A. Menarini Pte Ltd) in the optimization of BTcP in cancer patients.

Treatment-free remission: Who, how and why?

21 May 2018

At the recent American Society of Haematology Annual Meeting 2017, Professor François-Xavier Mahon reviewed recent studies related to tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukaemia (CML) who have achieved sustained deep molecular response (DMR).

Improving survival with CDK4/6 inhibitors in postmenopausal HR+/HER2-metastatic breast cancer patients

Rachel Soon, 28 Feb 2018

Recent developments on CDK 4/6 trials in patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC) were reviewed at ESMO and ASCO 2017.

Highlights from ESMO Asia 2017: Moving to a dual blockade strategy early in hormone receptor-positive breast cancer

22 Jan 2018

In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.

AMH may not predict oocyte yield in breast cancer patients

Pearl Toh, 29 Aug 2018

Levels of anti-Müllerian hormone (AMH) may not correlate with ovarian reserve in patients with breast cancer, suggests a study presented at ESHRE 2018, thus raising questions on the utility of AMH testing before hormonal stimulation in fertility preservation for women with breast cancer.

Higher rate of cancer, all-cause mortality among teens, young adults with perinatally acquired HIV

Roshini Claire Anthony, 29 Aug 2018

Teenagers and young adults living with perinatally acquired HIV (PaHIV) have a higher risk of developing malignancies and a higher all-cause mortality rate than their non-HIV-infected peers, according to a study from the UK.

Younger lymphoma patients may be less susceptible to chemo-induced ovarian toxicity

Pearl Toh, 27 Aug 2018

Chemotherapy may be less damaging to fertility of female lymphoma patients who are of a younger age than those who are older, even in the case of an alkylating regimen, suggests a study presented at ESHRE 2018.

Post-ICSI prostate cancer risk not caused by procedure

Roshini Claire Anthony, 25 Aug 2018

The increased risk of prostate cancer, particularly early-onset prostate cancer, among subfertile men who undergo intracytoplasmic sperm injection (ICSI) does not appear to be due to the procedure, according to a nationwide, registry-based study from Sweden.

CD4/CD8 ratio may predict risk of Kaposi sarcoma, NHL in HIV patients

Pearl Toh, 23 Aug 2018

Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.

Adolescent non-gynae cancer survivors may have increased infertility risk

Roshini Claire Anthony, 10 Aug 2018

Adolescent and young adult female survivors of certain non-gynaecological cancers may have an elevated risk of infertility with parity playing a role in this risk, according to a study from Canada.

Assisted reproduction not tied to long-term ovarian cancer risk

Roshini Claire Anthony, 04 Aug 2018

Women who undergo assisted reproductive technology (ART) treatment for infertility appear to have an elevated risk of ovarian cancer, but the lack of long-term association suggests that detection bias as well as parity and cause of infertility may play roles and not ovarian stimulating hormones, according to a study from Denmark.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!